Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Apixaban

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT02585713Phase 3Completed

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Showing all 1 trials

Research Network

Common Treatments

  • Apixaban1
  • Dalteparin1
  • Questionnaire Administration1

Active Sponsors

  • Academic and Community Cancer Research United1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Renal Vein Thrombosis1
  • Portal Vein Thrombosis1
  • Malignant Neoplasm1
  • Cerebral Vein Thrombosis1
  • Pulmonary Embolism1

Activity Timeline